gms | German Medical Science

42. Jahrestagung der Gesellschaft für Tropenpädiatrie und Internationale Kindergesundheit

Gesellschaft für Tropenpädiatrie und Internationale Kindergesundheit e. V.

12.04. - 14.04.2024, Eisenach

Article

Send article

Effect of IPTp on malaria in pregnancy and maternal, fetal and neonatal outcome – community-based research

Meeting Abstract

Search Medline for

  • presenting/speaker Hellen Barsosio - Malaria Program & Maternal & Newborn Health Studies, KEMRI-CGHR, Kenya

Gesellschaft für Tropenpädiatrie & Internationale Kindergesundheit. 42. Jahrestagung der Gesellschaft für Tropenpädiatrie und Internationale Kindergesundheit. Eisenach, 12.-14.04.2024. Düsseldorf: German Medical Science GMS Publishing House; 2024. DocL22

doi: 10.3205/24gtp19, urn:nbn:de:0183-24gtp197

Published: November 4, 2024

© 2024 Barsosio.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Over the past 15+ years, the malaria in pregnancy research community has been searching for alternative drugs to prevent malaria during pregnancy due to increasing parasite resistance to the two antifolate drugs currently used for chemoprevention in pregnancy: monthly sulphadoxine-pyrimethamine (SP) in HIV-negative women given from 2nd and 3rd trimester and daily cotrimoxazole (CTX) in pregnant women living with HIV. These two drugs share the same drug targets impacted by the parasite resistance patterns seen in eastern and southern Africa. Dihydroarteminisin-piperaquine (DP), a safe, well-tolerated long-acting ACT providing prophylaxis cover for up to 28 days, is currently the most promising candidate to emerge from years of clinical trials that could be added to SP or daily CTX to prevent malaria during pregnancy. The results of these trials will present findings from a clinical trial in Kenya and Malawi that evaluated the combination of CTX and monthly DP in preventing malaria during pregnancy in women living with HIV.